Marksans Pharma · NSE: MARKSANS · BSE: 524404
Q2 FY21 results · Jul–Sep 2020
Marksans Pharma reported revenue from operations of ₹356.47 crore (up 39.0% from Q2 FY20) and net profit of ₹50.73 crore (up 95.4% from Q2 FY20) for Q2 FY21 (Jul–Sep 2020), on a consolidated basis.
| Item | Q2 FY21 | Q2 FY20 | YoY | Q1 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 356.47 | 256.40 | +39.0% | 331.15 | +7.6% |
| Other income | 3.67 | 7.88 | −53.5% | 0.18 | 20x |
| Total income | 360.14 | 264.28 | +36.3% | 331.33 | +8.7% |
| Profit before tax | 65.90 | 33.66 | +95.8% | 61.40 | +7.3% |
| Net profit for the period | 50.73 | 25.97 | +95.4% | 49.37 | +2.8% |
| EPS, basic (₹) | 1.21 | 0.63 | +92.1% | 1.20 | +0.8% |
| Net margin (%) | 14.2 | 10.1 | 14.9 |
| Item | Q2 FY21 | Q2 FY20 | YoY | Q1 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 137.55 | 100.72 | +36.6% | 155.96 | −11.8% |
| Other income | 12.96 | 7.87 | +64.7% | 0.05 | 264x |
| Total income | 150.51 | 108.58 | +38.6% | 156.01 | −3.5% |
| Profit before tax | 31.01 | 15.53 | +99.7% | 24.92 | +24.4% |
| Net profit for the period | 23.53 | 11.86 | +98.4% | 22.06 | +6.7% |
| EPS, basic (₹) | 0.57 | 0.29 | +96.6% | 0.54 | +5.6% |
| Net margin (%) | 17.1 | 11.8 | 14.1 |
Consolidated
- Filed with BSE
- 09 Nov 2020, 17:57 IST
- Board meeting
- 06 Nov 2020
- Period
- 01 Jul 2020 to 30 Sep 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 09 Nov 2020, 17:57 IST
- Board meeting
- 06 Nov 2020
- Period
- 01 Jul 2020 to 30 Sep 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE